Botanix Pharmaceuticals (ASX:BOT) received firm commitments to raise AU$40 million via a non-underwritten institutional placement, according to a Tuesday filing with the Australian bourse.
The placement is for the issue of roughly 121.2 million new fully paid ordinary shares at AU$0.33 apiece. The price is a 7% discount to the company's last traded price before the trading halt on April 14, per the filing.
Proceeds will be used to fund the commercialization of Sofdra in the US. Sofdra aims to treat primary axillary hyperhidrosis.
Botanix Pharmaceuticals' shares were up past 10% in recent Tuesday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。